<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003133</url>
  </required_header>
  <id_info>
    <org_study_id>97-106</org_study_id>
    <secondary_id>CDR0000065899</secondary_id>
    <secondary_id>NCI-G97-1358</secondary_id>
    <nct_id>NCT00003133</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer</brief_title>
  <official_title>Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy following&#xD;
      surgery in treating patients with advanced bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety and toxicity of sequential dose intensive adjuvant&#xD;
      systemic therapy consisting of gemcitabine, then doxorubin, followed by paclitaxel and&#xD;
      cisplatin with filgrastim (granulocyte colony stimulating factor; G-CSF) for patients with&#xD;
      completely resected, locally advanced transitional cell carcinoma of the urothelium. II.&#xD;
      Assess the disease free and overall survival of these patients.&#xD;
&#xD;
      OUTLINE: Patients receive gemcitabine IV on weeks 1, 2, 3, 5, 6, and 7 for a total of 6&#xD;
      doses. A 1 week rest period occurs after the third dose of gemcitabine. At least 14 days&#xD;
      after the last dose of gemcitabine, during the ninth week, patients receive doxorubicin at 2&#xD;
      week intervals (weeks 9, 11, 13, and 15) for a total of 4 doses. Filgrastim (granulocyte&#xD;
      colony stimulating factor; G-CSF) is administered subcutaneously on days 3-10 of each cycle&#xD;
      of doxorubicin. At least 14 days after the last dose of doxorubicin, during week 17, patients&#xD;
      receive the combination of paclitaxel IV (3 hour infusion) and cisplatin, at 2 week intervals&#xD;
      (weeks 17, 19, 21, and 23) for a total of 4 doses. G-CSF is again administered on days 3-10&#xD;
      of each of these cycles. Patients are followed every 3 months for the first 2 years, every 6&#xD;
      months for the next 3 years, then annually until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue 25-30 patients in 1.5-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1997</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Pathologically proven complete resection of locally advanced&#xD;
        transitional cell carcinoma of the urothelium with negative margins Disease extends beyond&#xD;
        the bladder, the ureter, or into the regional lymph nodes Stages eligible for patients with&#xD;
        bladder cancer: Tany, N+, M0 T3b, N0, M0 T4a, N0, M0 Stages eligible for patients with&#xD;
        urothelial cancer of the renal pelvis or ureter: Tany, N+, M0 T3, N0, M0 T4, N0, M0 Local&#xD;
        control of primary urothelial tumor obtained by: Cystoprostatectomy plus pelvic lymph node&#xD;
        dissection for bladder cancer in males Cystectomy/TAH/BSO and pelvic lymph node dissection&#xD;
        for bladder cancer in females Nephroureterectomy for disease involving the renal pelvis or&#xD;
        ureter&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% ECOG 0-1&#xD;
        Life expectancy: Not specified Hematopoietic: Platelet count at least 150,000/mm3&#xD;
        Granulocyte count at least 1500/mm3 Hepatic: Bilirubin less than 1.5 times normal SGOT and&#xD;
        alkaline phosphatase less than 2 times normal Renal: Creatinine less than 1.5 mg/dL OR&#xD;
        Creatinine clearance at least 60 mL/ min Cardiovascular: LVEF at least 50% No New York&#xD;
        Heart Association class II or IV heart disease No serious cardiac arrhythmias, including&#xD;
        first, second, or third degree heart block Other: No concurrent second malignancy except&#xD;
        nonmelanomatous skin cancer or curatively treated in situ carcinoma of the cervix No&#xD;
        uncontrolled infection Fertile patients must use barrier method contraception before,&#xD;
        during, and for 6 months after therapy and are encouraged to continue barrier method&#xD;
        contraception for 2 years or longer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior systemic&#xD;
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior irradiation of the&#xD;
        bladder Surgery: See Disease Characteristics Definitive surgery performed within 10 weeks&#xD;
        of study treatment start&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean F. Bajorin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2004</study_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <keyword>stage III bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

